It’s not that they are close, we’ve talked a lot about it, it’s how Chinese frame it and celebrate it… It’s like seeing your world through the eyes of an alien civilization.
The seventh generation of the Rothschild banking dynasty will take over the centuries-old bank this summer, according to the Financial Times.
Controversy and conspiracy theories over the family’s supposed control of wealth have long existed in the West, but in recent decades more and more Chinese economists and budding entrepreneurs have closely studied the Rothschilds.
At the same time, members of the Rothschild family have looked to a rising China for new business opportunities.
The next generation
According to the Financial Times, Alexandre de Rothschild will take over as chairman of Rothschild Bank from his father David de Rothschild this summer, with the 37-year-old expected to lead the way in diversifying the group beyond “its core French and British advisory business.”
Outgoing Chairman David de Rothschild. /VCG Photo
Alexandre de Rothschild joined the family business a decade ago, overseeing a period when the bank has looked to push beyond Europe in terms of investment strategy.
In fact, the Rothschild family came to China as long ago as the 1830s, when it set up a small gold and silver trading business in Shanghai. In 1953, four years after the founding of New China, Rothschild was one of the first major Western banks to establish relations with the country.
A history of investments in China
In 2008 La Compagnie Financiere Edmond de Rothschild (LCFR), the bank’s French branch, was on the verge of securing 2.3 billion yuan (336 million US dollars) worth of investment from the Bank of China. That deal however fell through after failing to get approval from the Chinese government.
In 2011, UK-based Rothschild subsidiary RIT Partners set up one of the first private equity funds in China to raise renminbi in the country and invest it overseas, with a target of amassing 750 million US dollars within its first year.
Alexandre de Rothschild (L) with CEFC China Energy Chairman Ye Jianming in Shanghai, May 2017. /China Daily Photo
Last year, Alexandre de Rothschild met with Ye Jianming, chairman of CEFC China Energy, with both sides agreeing to strengthen cooperation in sectors including energy, financial services, aviation, infrastructure construction, food and high-end property management.
China’s fascination with the Rothschilds
Beyond its growing financial presence in the country, the past decade has seen growing cultural awareness in China of the Rothschild family.
Several bestselling but controversial books have seen a wave of interest in Jewish business practices, particularly among wealthy entrepreneurs and investors looking to establish their own family legacies.
Published in 2007, Song Hongbing’s Currency Wars was an instant success in China, with publisher CITIC claiming there were some 600,000 copies in circulation within months of it being released.
In the book, Song, who studied and lived in the US from 1994 and worked as an IT consultant, claims the Rothschild family control five trillion US dollars’ worth of global wealth.
Song’s work was widely criticized in the West as an “economic novel,” and lambasted for promoting anti-Semitic conspiracy theories.
The Financial Times reported that Currency Wars was widely read by Chinese company heads and government officials, with Song himself saying “I never imagined it could be so hot and that top leaders would be reading it.” He insisted that the book was not anti-Semitic.
Jon Benjamin, then the chief executive of the Board of Deputies of British Jews, told the Financial Times he was concerned by the book, and was worried that the Rothschild conspiracy theory was gaining traction “in the world’s most important emerging economy,” despite China having “little or no concurrent culture of anti-Semitism.”
Song Hongbing, who currently has almost two million followers on Sina Weibo, has gone on to publish five books in his Currency Wars series, and since 2007 more and more books on the Rothschilds and more generally on so-called Jewish business practices have been published.
Chinese books on Jewish business practices, from top left, clockwise: How do Jewish People win?; Jewish Business Bible; Jewish Businessmen’s Wisdom; Jewish Business Teachings. /Images from China Daily, Douban
Titles such as “The Legend of Jewish Wealth,” “Jewish Family Education” and “The Illustrated Jewish Wisdom Book” can all be found in the business sections of bookstores across China.
Han Bing, who wrote business self-help guide “Crack the Talmud,” told Newsweek in 2010 that Jews and Chinese shared historic and cultural similarities. When pressed on whether his book was promoting stereotypes, Han admitted that he had never met a Jewish person in his life.
Falling for fake wine and frauds
The Rothschild name is also synonymous with Chateau Lafite in China, one of the most popular wine labels for the country’s wealthiest people.
Selling for as much as 10,000 US dollars per bottle, Xinhua reported in 2011 that the majority of Lafite sold in China could be fake, as sales figures reported in just Zhejiang Province were exceeding official global production figures.
Beyond fake bottles of Rothschild wine, a man named Oliver Rothschild who pretended to be part of the banking dynasty infamously fooled Tsinghua University in 2016.
The British man was given the red carpet treatment by the university, with Dean Qiu Yong calling him “one of the successors of the Rothschild family,” and claiming he was a former head of UNICEF.
The real Rothschild family released a statement saying Oliver Rothschild was not connected to the family in any way, after reports that he had traveled around China for several years giving speeches under the guise of being part of the banking family.
The “fake Rothschild” Oliver Rothschild in 2014. /VCG Photo
After Tsinghua admitted it had fallen for the fraud, The Global Times said the story showed China’s “longing for international endorsement, especially from the developed world, as an indicator of being something.”
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
! Articles can always be subject of later editing as a way of perfecting them
IF YOU’RE READING THIS, YOU’RE PROBABLY TARGETED BY A GOVERNMENT OR TWO. SO I MADE SOMETHING FOR YOU. SEE DETAILS / ORDER
Joe Biden should be in a diaper in a nursing home and not spreading fear.
Vladimir Zev Zelenko MD
journals.plos.org
Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses…
Author Summary Positive-stranded RNA (+RNA) viruses include many important pathogens. They have evolved a variety of replication strategies, but are unified in the fact that an RNA-dependent RNA polymerase (RdRp) functions as the core enzyme of their RNA…
On DECEMBER 12, 2019 an agreement was signed (pg 105) that Dr. Ralph Baric of the University of North Carolina would receive "mRNA corona virus vaccine candidates developed and jointly-owned by NIAID and Moderna"@Rossana38510044@ydeigin@BillyBosticksonhttps://t.co/taAbB9FIvp
Full text: Coronavirus Research Conducted by Dr. Ralph Baric’s Team at University of North Carolina2021-11-09 10:45
The full text of the non-paper entitled “Coronavirus Research Conducted by Dr. Ralph Baric’s Team at University of North Carolina.”
Dr. Ralph Baric and his team from the UNC have been systematically working on coronavirus-related researches for a long time, including Gain-of-Function (GOF) research. They possess synthetic biology techniques used for manipulation and modification of coronavirus genome and have applied for multiple patents related to coronavirus research.
In the aftermath of the SARS outbreak in 2003, the Baric team collaborated with the United States Army Medical Research Institute of Infectious Disease (USAMRIID) and developed a novel reverse genetic system for synthesis of a full-length cDNA of the SARS-CoV, which was published in a paper in 2003. The paper claimed that within two months after obtaining the RNA of the SARS virus, the full-length cDNA of the virus was successfully synthesized, which shows that as early as 2003, these institutes already had advanced capabilities to synthesize and modify SARS-related coronavirus.
In December 2008, Dr. Baric co-authored another paper on the successful reconstitution of a chimeric virus with the genome backbone from a bat SARS-like coronavirus and the receptor binding domain (RBD) from SARS-CoV using similar synthetic biology techniques, arguing that the design and synthesis of various SARS-related coronaviruses are important steps to prevent similar outbreaks in the future.
It is worth noting that the Baric team has close collaboration with the USAMRIID, and they co-own the patent related to manipulation of coronavirus genome and have published multiple papers together. The scope of this cooperative relationship was further expanded after Lisa Hensley, one of Dr. Baric’s students, joined the USAMRIID.
In November 2015, the Baric team published a paper titled “A SARS-like Cluster of Circulating Bat Coronaviruses Shows Potential for Human Emergence”. According to the paper, a chimeric coronavirus was made with the genome backbone from a mouse-adapted SARS-CoV virus provided by the U.S. team and the RBD from a bat SARS-related CoV SHC014 discovered by Zhengli Shi’s team from the Wuhan Institute of Virology. Dr. Baric’s lab tested the pathogenesis of the chimeric virus in mice and even reconstituted the full length SHC014 virus. In this study, both the virus modification and the experiment on mouse infection were conducted at the UNC and the chimeric virus was not provided to Shi’s team.
Some people in the United States claim that GOF researches by the Wuhan Institute of Virology have caused bat coronaviruses to mutate into SARS-CoV-2 and a lab leak led to the COVID-19 pandemic. As a matter of fact, the United States have sponsored and carried out more such researches than any other country. In particular, the Baric team leads the world in researches in this field. A thorough investigation into Dr. Baric’s lab will help clarify whether such researches have led to or can lead to SARS-CoV-2.
Remember when ferritin in Covid bioweapons was a conspiracy theory and we were getting our YouTube channels and socials wiped out for exposing it? That was fun!
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Except in the process of “doing it”, very interesting undisclosed trades have occurred.
An amazing researcher / whistleblower, former pharma and medical device R&D executive Sasha Latypova has recently confirmed and furthered our research on several topics. Here’s a fragment from a recent Substack post:
I know what is in the redacted part of the above paragraph and it was not hard to figure out. The first redaction under 1.1.1 BACKGROUND is “Fosun Pharmaceuticals”, so the sentence reads “Fosun Pharmaceuticals”, Pfizer and BioNTech entered into an agreement for the co-development…”
Note: the only journalist I am aware of in either “mainstream” or “resistance” who mentioned Fosun was Naomi Wolf, kudos to her. I was in touch with The Epoch Times to try to publish this information, and even they decided to bury the story (but they published my other materials). I did discuss this on Dr. Jane Ruby’s show, and kudos to her as well for not being afraid to cover the truth.
Below is the timeline of some of the key investments and R&D deals I was able to identify from public SEC shareholder disclosures, immediately preceding and following the “pandemic”:
Just to make sure, we are talking about the exact technology in the mRNA shots. Here is the definition from March 17, 2020 agreement between Pfizer and BioNTech (p. 4):
The same document describes a data sharing agreement, “pharmacovigilance” globally among the 3 parties. They will count the bodies and share the data with each other:
On the “pharmacovigilance” aspect, there is a 4th participant in this arrangement – the Israeli Ministry of Health, which entered into a data sharing agreement with Pfizer on January 6, 2021 and gave Pfizer (and by extension, US DoD and anyone who controls it, BioNTech and anyone who controls it, Fosun and anyone who controls it, i.e. CCP) access to all their citizens’ centralized electronic health records. But don’t worry, Benjamin Netanyahu promised to keep the data de-identified. Right.
Side note – Israeli government recently “misplaced” the Manufacturing and Supply Agreement with Pfizer mentioned in the data sharing agreement above (so we know for sure it exists). The government sadly cannot find it for some reason…
This gets even larger and more interesting when looking at the sources of “R&D” financing. Turns out, there were numerous financial backers and co-investors in the BioNTech “venture” in the years preceding the global fraud and mass murder exercise. According to Crunchbase, BioNTech, a tiny company with just a handful of employees and NO PRODUCTS or scale manufacturing, raised $1.7B in 9 rounds of investments since around 2008. Large portion of the money, $1B+ was raised before 2020. What was it for, since no big clinical trials or scale manufacturing was happening then? That’s a good question, worth examining at some point. Cursory review of some of the investment rounds indicates wide and very international involvement of a variety investors from US, Europe, UK, Australia, South Africa, mainland China, Hong Kong and Singapore among others. These likely included many government actors: “sovereign” funds, pension funds and the like who often do these investments by allocating money to “private venture funds” (limited partners in a private venture funds are confidential). Maybe I will do a separate article on this at a later date.
Note, many people ask me “what about China and Russia?” when I talk about our own government and DoD engaged in mass genocide of Americans. I answered about China – they are allied with the US DoD on this. The CCP is profiting from the financial windfall of the US government printing dollars and throwing them into the mRNA furnaces where they are driving masses of the brainwashed citizens to suicide themselves. China claims to use “traditional vaccines” – if you believe what the Chinese say, I have a bridge to sell you.
I have not seen evidence of any similar alliance with Russia. This makes sense, because ultimately this boils down to the war of US vs Russia using proxies and alliances (as it always does). This does not mean that Russia are “the good guys”. Simply that the owners of Russia (whoever they are, not necessarily based in Russia) disagree with the owners of the US (whoever they are, not necessarily based in the US). Russia is running the same “covid script”, using knock off RNA/DNA injections, probably buying materials from the same suppliers, and also using war to kill off their own younger population. It’s just that they are doing it for THEIR OWN interests, not that of the US and their allies. – Sasha Latypova
For more context and a larger horizon on the topic, you also need to see this essential piece:
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Some of my best efforts to help with the current state of general confusion, I hope it works! And if it does, please remember to share it!
I don’t talk much about myself because I don’t want or need to leverage my persona / CV / bio to support anything I say. If my arguments don’t speak for themselves, my CV is useless and it won’t really speak for the facts.
However, this time it’s particularly relevant where this is coming from, because many years ago I was a fake news operative in the country that borders Ukraine to the south. In other words, I was a mainstream news journalist in Romania, a media mercenary, a low/middle echelon disinformation agent exactly like those exposed by Project Veritas. This was long ago in my life’s timeline, but historically it was yesterday, around the same time Putin was raising to fame. 9/11 caught me at my desk in a radio station’s news dept. I shook hands with all Romanian presidents after Ceausescu, I partied with much of today’s political class there, attended international meetings etc. And today’s Ukraine and its deep state resembles quite a lot 1990’s / early 2k Romania. This experience offered me not only great deep insights of the system, but also the ability to reverse-engineer news to the point where I can often see the real story behind a propaganda news piece, I can tell what the writer thought doing it, what his editor’s thoughts were and who financed it. Because I played all those positions and more. I quit all that for an artistic career just the last second before getting completely sucked in for life, I left because I grew disgusted with myself and the people who saw me as their asset. Then I left the country completely. I am sorry sorry for what I did, but I don’t apologize or excuse myself, instead I just did the work I thought fit to to redeem myself in my own eyes, to fix what I can in this world. Not because I’m a great altruist and I love you so much I lose sleep over it, but because I love myself and I don’t fare well as part of the problem in a slave farm. This where this work comes from. As for my biases, I’ not a fan of and I have no loyalty to any group of people, the largest the worse, with the exception of music concert and festival audiences. I think all governments are terrorist organizations, all ideologies are dumb BS by their core definition and good people don’t dream of ruling over others or leading them. And from where I stand, this is what I see:
FULL
A higher resolution downloadable version will be uploaded next days on our Odysee. Feel free to reupload it, I just hope you will link back to the source.
I strongly recommend watching it as I meant it and built it – in one séance, but if you can’t, for whatever reasons…
Now, this took a hell lot of effort and time, and I have another one in works that helps understanding how we got here. A prequel, if you wish. It could’ve been done by now, but my equipment is aging fast, its performances are slow and getting slower, while I am refused my normal existence and means to earn it, except for your voluntary donations. So any help is much needed and appreciated these days, many many thanks go to the generous souls that have made this possible so far! It meant something, we’ve already made a serious impact.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
This might be the biggest news since Covid and, four days later, no one is talking about it. So big it’s worth sounding war drums to cover it. Some scientists say it’s a 1/3trillion coincidence, others say it’s nothing amazing. I propose a my own solution to this debate.
The facts:
In a new study, published only four days ago in Frontiers in Virology, researchers compared the SARS-COV-2 makeup to millions of sequenced proteins in a database, finding a coincidence that they deem as a 1/3trillion mathematical probability. The other element of the coincidence is the notorious Moderna 2016 invention patent for a technology included in a precursor to the Covid mRNA vaccine, the cancer mRNA jab they were working on at the time.
The virus is made up of 30,000 letters of genetic code that carry the information it needs to spread, known as nucleotides.
Analysis of the original Covid genome found the virus shares a sequence of 19 specific letters with a genetic section owned by Moderna, which has a total of 3,300 nucleotides.
The few scientists that have reacted to this discovery so far haven’t denied it. But some denied its importance and relevance, stating simplistically that 19 nucleotides out of 3300 is not much and can be a natural coincidence, possibly driven by common evolutionary needs. Except the patent is not the fruit of natural evolution, it wouldn’t be patentable if it were natural.
“Twelve of the shared letters make up the structure of Covid’s furin cleavage site, with the rest being a match with nucleotides on a nearby part of the genome. Writing in the paper, led by Dr Balamurali Ambati, from the University of Oregon, the researchers said the matching code may have originally been introduced to the Covid genome through infected human cells expressing the MSH3 gene. Professor Lawrence Young, a virologist at Warwick University, admitted the latest finding was interesting but claimed it was not significant enough to suggest lab manipulation. He told MailOnline: ‘We’re talking about a very, very, very small piece made up of 19 nucleotides. ‘So it doesn’t mean very much to be frank, if you do these types of searches you can always find matches. ‘Sometimes these things happen fortuitously, sometimes it’s the result of convergent evolution (when organisms evolve independently to have similar traits to adapt to their environment). ‘It’s a quirky observation but I wouldn’t call it a smoking gun because it’s too small. He added: ‘It doesn’t get us any further with the debate about whether Covid was engineered.’ Dr Simon Clarke, a microbiologist at Reading University, questioned whether the find was as rare as the study claims. He told MailOnline: ‘There can only be a certain number of [genetic combinations within] furin cleavage sites. ‘They function like a lock and key in the cell, and the two only fit together in a limited number of combinations. ‘So it’s an interesting coincidence but this is surely entirely coincidental.’
Say what?!?!
“MailOnline has approached Moderna for comment.”
UDATE: Daily Mail couldn’t get a comment from Moderna, but Fox could. And it’s spectacular in its own very special way:
And I have reasons to think those guys suck balls and very likely this is the biggest news since Covid, hear me out:
This news is a perfect case study for a point I’ve been making for a long while: things in Universe exist in either of these three states:
Natural occurrence beyond human influence aka COINCIDENCES
2. The aimed result of human deliberation and activity aka CONSPIRACIES.
3. A combination of 1. and 2. aka CONSPIRACIES GONE HAYWIRE, which I think describes 99% of human life experience.
And, based on history, lived or learned, pure coincidences are way more rare than pure conspiracies, or mixtures, so favoring coincidences over conspiracies is simply dumb and ignorant.
Thus, Coincidence theorists are the ones who deserve the most scrutiny, mockery and ridicule. In the human society, as opposed to nature, coincidence theories should be more seriously scrutinized than conspiracy theories.
It is crucial to find alternative ways to solve such a debate with means that are accessible to anyone that’s just a functional literate.
THE DISCUSSION
Is that nucleotide sequence a stunningly unlikely coincidence or just nothing special?
“One in three trillion” or “once in a while”?
How do we arbiter this high-expertise debate without having that expertise and without relying on pre-chewed opinions from dubious or biased experts?
I have a bachelor degree in journalism and public communication, and I’ve always been deeply interested in science even since before school. I have studied health (not just medicines) and physiology for my own understanding, use and benefit for over 20 years now. As a result, I haven’t used any medication in close to 15 years now. That’s where expertise ends for me. People with other occupations and passions need to be able to make their own minds on this because ‘expert’ nowadays is the politically correct term for whores.
I can’t calculate complicated probabilities, nor do I have the education and the practical experience of a virologist, as the majority of any media readership. But they don’t have my education either, and I bet you it’s just as useful.
So does this mean we can’t find a way to skin this cat and we have to take these conmen’s word?
Don’t be silly. This is SILVIEW.media
When it comes to chance and ‘probabilistics’, the most common reference is the lottery. Not so popular among the young ones, but I hope they have a grasp of it too. At least through some online games.
There are many models, I don’t play, I’ll just pick one that I remember from home. It’s called “6 out of 49”. As the name suggest, from the numbers 1-49 they randomly pick 6 and you have to guess all of them. But they give you a decent prize even if you have five matches, because that’s extraordinary enough.
VERY IMPORTANTLY: 1. The order doesn’t matter. 2. The numbers don’t mean anything, they don’t have any function, nor do they make up a system.
There’s been years without any claim for the grand prize there. That’s how rare this coincidences are.
Now, in our dilemma we have a huge stream of only four characters, as the genome is made up of only four nucleobases: guanine, adenine, cytosine and thymine; in RNA, uracil is used in place of thymine. They are symbolised with the letters A, C, G, T. Not by coincidence, they also form the name Gattaca.
So, in our genetic coincidence theory we have a stream of 3300 of these four elements and another one of 3000, and a fragment of 19 elements coincides between the two streams. Is that so amazing?
Maybe a superficial face value estimate, by the lottery model, “19 out of 3000” sounds insignificant, but that’s the wrong equation here.
Remember: 1. The order 2. The function
It’s not in the numbers, but in the succession and the function
As opposed to lottery, what surprises here is not that we have matching elements, but a massive matching sequence of elements. That’s a whole new level of complexity. We’re dealing with a mathematical combination of four elements taken 19 times. Now that mathematical function will yield a gigantic number of possibilities.
And then something takes things to a whole new level: the sequence is not just some random fragment from the character streams, it’s a full subsystem with its own functionality.
Twelve of the shared letters make up the structure of Covid’s furin cleavage site, with the rest being a match with nucleotides on a nearby part of the genome.
And it’s not just any function, they are debating if this is what makes it more contagious, as in ‘the capabilities they add to viruses through gain-of-function research’!
Scientists do not yet fully understand how individual mutations in SARS-CoV-2 variants influence contagiousness or disease severity.
To enter a human cell, the SARS-CoV-2’s spike protein must be activated. This happens following cleavage by an enzyme called furin.
Scientists have theorized that mutations at the furin cleavage site might play an important role in a variant’sability toinfect or replicate in human cells.
Contrary to expectations, the authors of a new study found that this mutation did not influence the ability of the virus to enter or spread between cells.
Some variants of concern, such as Delta and Omicron, also have mutations at the same furin cleavage site, and this study may help understand the changes in their contagiousness and ability to produce disease.
If it were a random coincidence, it wouldn’t have a meaning / function of its own, it would be… random.
How do you get from:
“Dr Simon Clarke, a microbiologist at Reading University, questioned whether the find was as rare as the study claims. He told MailOnline: ‘There can only be a certain number of [genetic combinations within] furin cleavage sites. ‘They function like a lock and key in the cell, and the two only fit together in a limited number of combinations. “
to:
“So it’s an interesting coincidence but this is surely entirely coincidental.”
Absolute non-sequitur. They literally demonstrated the opposite of their conclusion. They simply count on you not critically analyzing things, just skimming headlines.
Because coincidence theorists are fucking dumb.
I mean, is it even theoretically possible if we factor in all the discussion above? What would be the likeliness? Sounds somewhere in the range of one in trillions to me. I’d personally round it up to an infinite.
While we can’t extract precise numbers with this method of reasoning, we can establish that this is the biggest lottery ticket ever won.
Disclaimer: this article does not imply that SARS-COV-2 exists in any other form and shape than a stream o characters on some computer hard drives. That’s all we’ve seen and analyzed here.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
We warned you that giving these people free access to your body is a bad idea, for they will take advantage to put in and take out all sorts of things you don’t know about. Just like they do with everything else.
If you’ve been around for a while, this doesn’t really surprise you, but it’s a valuable confirmation and we can move over with this discussion.
If not, you definitely need to catch up with this too:
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
The Internets got agitated recently at the news that Moderna’s CEO, Stephane Bancel, dumped $400Million in Moderna stocks and nuked his Twitter account. Here’s why this shouldn’t surprise you and you should expect the worst any moment now.
Have you watched the former Blackrock director that went on Bannon’s War Room and prophesied that the Covid vaccines are a bubble that’s about to pop? Everything I’ve learned lately stands to support his claim.
If the dumping were a sudden and unusual move, this would indicate a recent event that shook the system, possibly rats leaving a sinking ship, a near threat for the business, as in:
That’s the case only partly, due to the stock crash overlapped with the incoming financial report, but a constant behavior over the span of months and years rather indicate a strategy and it’s associated with insider trading more often than not.
Surprisingly, it’s NPR of all the fakestream media who came in support of my suspicions, with a pretty merciless analysis of Moderna’s leadership financial behavior. And you know what’s funny? The piece dates all the way back to September 2020. I recommend reading the whole piece, I added the bolding and highlights :
Whether the coronavirus vaccine developed by Moderna succeeds or not, executives at the small biotech company have already made tens of millions of dollars by cashing in their stock. An NPR examination of official company disclosures has revealed additional irregularities and potential warning signs.
“On a scale of one to 10, one being less concerned and 10 being the most concerned,” said Daniel Taylor, an associate professor of accounting at the Wharton School, “this is an 11.”
Taylor said Moderna’s stock-selling practices appear well outside the norm, and raise questions about the company’s internal controls to prevent insider trading.
Since January, CEO Stéphane Bancel has sold roughly $40 million worth of Moderna stock held by himself or associated investment funds; Chief Medical Officer Tal Zaks has sold around $60 million; and President Stephen Hoge has sold more than $10 million.
Stéphane Bancel, chief executive officer of Moderna, has sold roughly $40 million worth of stock in the company since the beginning of this year.
The stock sales first came to widespread notice after Moderna announced positive early data from a vaccine trial in May [2020 – S.m.]. At that point, the company’s share price jumped and official disclosures showed executives cashing in their shares for millions of dollars.
“As long as stocks are sold after public announcements – and not before – one might conclude that for an executive with significant net worth tied up in the company, it’s a prudent thing to do,” said Marc Fagel, a former longtime enforcement official with the Securities And Exchange Commission (SEC). “But the optics aren’t great.”
The Moderna vaccine was quick to reach a phase 3 trial, and is seen as a promising contender. But, in some ways, the executives’ stock sales have overshadowed the company’s progress.
Advocates have questioned whether it’s appropriate for executives to privately profit before bringing the vaccine to market, especially when American taxpayers have committed roughly $2.5 billion to the company’s vaccine development and manufacture.
Here’s what NPR’s examination found:
Stock Sales Worth Tens Of Millions: Since June 1, NPR has found, company executives have sold roughly $90 million worth of Moderna stock. Rather than put a hold on the trades after facing intense criticism in May, company executives continued to sell.
Questionable Modifications To Stock Sale Plans: Moderna says its executives pre-scheduled their stock sales long in advance. Those schedules – known as 10b5-1 plans – can act as a defense to charges of insider trading. But the plans have to be put in place when executives do not have confidential inside information. NPR has found multiple executives adopted or modified their plans just before key announcements about the company’s vaccine. That has raised questions about whether they were aware of nonpublic information when they planned their stock trades.
Selling To Zero: Generally, corporate best practices suggest that a company’s leadership should hold on to at least some stock in their company to have “skin in the game.” That way, the thinking goes, an executive has an incentive to improve the company’s performance. As Moderna has been developing its coronavirus vaccine, two executives, including the Chief Medical Officer, have sold all their stock holdings in the company. The General Counsel has sold nearly all of her holdings.
In an interview with NPR, Ray Jordan, Moderna’s Chief Corporate Affairs Officer, said the company has strict internal policies in place to prevent illegal insider trading. For example, Jordan said, the company only allows employees to make changes to their stock sale schedules when they don’t have confidential inside information that could affect the company’s share price.
NPR asked Jordan why Moderna executives modified their 10b5-1 plans just before major announcements. Initially, Jordan said by email, “I believe you must have your dates wrong.”
NPR then provided documentation of those dates from the company’s official disclosures to the government, which Jordan did not dispute.
Jordan then said that even though multiple Moderna executives changed their 10b5-1 plans within one business day of announcements, the company had determined that those executives did not have “material nonpublic information” – a key term for insider trading – when they made those changes.
A spokesperson for the SEC declined to comment for this story.
From a relative unknown, to a key player in the vaccine race
Moderna launched in 2010 with a headquarters based in Cambridge, Mass., focused on using a technology called messenger RNA (or mRNA) to develop vaccines and therapeutics. The mRNA technology has been widely considered innovative, but remains largely unproven. The company has never brought a product to market. In early January, Moderna was trading for under $20 per share, and was valued at around six billion dollars.
Then Moderna announced that it had started collaborating on a coronavirus vaccine with scientists from the National Institute of Allergy and Infectious Diseases, which is led by Dr. Anthony Fauci.
By April, the government had committed half a billion dollars to the Moderna vaccine project as part of Operation Warp Speed.
Since then, the company’s stock price has exploded. Press releases suggesting positive news from the scientific trials, or announcing additional commitments of taxpayer funding sent the share price to a peak of around $95, before dropping to between $60-$70 in recent months. The company is now valued at around $25 billion.
As a result, shares owned by Moderna executives suddenly became much more valuable. And those executives have cashed in tens of millions of dollars worth of stock, according to filings with the SEC.
The bad press and critical comments did not deter continued sales. Since June 1, NPR found, executives sold around $90 million worth of stock.
Public money, private gain
The U.S. government is making massive financial bets on several vaccine candidates. In all likelihood, only some of those vaccine candidates will prove sufficiently safe and effective.
“If the vaccine doesn’t work, you lost a lot of money,” Fauci has said. “But we feel this is serious enough that it’s worth the financial risk.”
But even if taxpayers lose money betting on Moderna, the company’s executives have already made millions.
“The insiders are making plenty of profit and they’re mostly doing it with our money,” said Margarida Jorge, a campaign director with the group Lower Drug Prices Now. “I’m absolutely for deploying public money in the interests of public health and the public good. But we don’t have any commitment from the administration that any of this investment is ultimately going to benefit real people.”
Moderna has argued that the company was only in a position to work with the government on a coronavirus vaccine, because it had spent a decade developing its mRNA technology with the support of private investors.
“The company has been funded over the years by billions of dollars of private investment,” Zaks told the Freakonomics podcast in August. “Those billions created the opportunity for the U.S. government to come in earlier this year and say, ‘I’m going to add some money to the pot to make sure that you get the development for this vaccine right.'”
[But they locked in the Government and its funding for mRNA technology years before SARS-COV2, as shown below, so this was a deliberate lie – S.m]
Trying to resuscitate the company with some archive work?
“Set it and forget it” stock plans
Moderna has offered another defense of those stock sales: the sales, representatives and executives say, were scheduled well in advance, and were unrelated to the market-moving announcements about the coronavirus vaccine. An NPR examination of the company’s financial filings tells a more complicated story.
The schedules are known as 10b5-1 plans. If your stock trades are on autopilot, the idea goes, then you can’t be accused of insider trading. But these “set it and forget it” plans have to be adopted when executives do not have “material nonpublic information,” to use the legal term.
In an interview with CNBC in July, CEO Bancel said he and other executives set up their 10b5-1 plans “a long time ago” – in December 2018 – and “obviously, when we set up those plans, none of us had any idea what was going to happen in 2020.”
In fact, NPR has found, Moderna executives, including Bancel himself, implemented new plans or modified older plans at multiple points in 2020, and right around key announcements related to the company’s vaccine.
On Jan. 21, 2020, for example, Chief Medical Officer Dr. Tal Zaks amended his 10b5-1 plan. (It’s unclear what changes he made.)
Then, on Jan. 22, Moderna first widely confirmed that it was working with the government on a coronavirus vaccine. The following day, Jan. 23, the company announced it had received additional funding to support its coronavirus vaccine development.
NPR asked Moderna whether Zaks might have been aware of the collaboration with the government when he changed his stock trading plan.
“What was known on that particular day or not known, I couldn’t specifically talk to,” Moderna’s Jordan told NPR. But he said that the Moderna legal team only allows employees to change their 10b5-1 plans if they do not possess inside information that could affect the company’s share price.
Later, on Friday, March 13, three Moderna executives adopted new 10b5-1 plans, according to records reviewed by NPR: Zaks, Chief Technical Operations and Quality Officer Juan Andres, and then-Chief Financial Officer Lorence H. Kim. (Kim left the company in August 2020.)
On Monday, March 16 – one business day later – the company announced that it had given a participant the first dose of their vaccine as part of its phase 1 trial. The stock ended that day up 24% compared to the previous day’s close. Moderna was “bucking the trend” of the broader market, which was panicking over coronavirus fears, one CNBC host said at the time.
Timing Of Changes To Pre-Scheduled Stock Sales Raises Questions
Jan. 21 – Chief Medical Officer Dr. Tal Zaks amends his schedule of stock sales, known as a 10b5-1 plan.
Jan. 22 – Moderna widely confirms that it is working on a coronavirus vaccine with the National Institutes of Health. The company’s share price rises nearly 5% over the previous day’s close.
Jan. 23 – Moderna announces new funding from the Coalition for Epidemic Preparedness Innovations.
Mar. 13 – Chief Technical Operations Officer Juan Andres, Chief Financial Officer Lorence Kim, and Zaks adopt new 10b5-1 trading plans.
Mar. 16 – Moderna announces that it provided the first dose of its coronavirus vaccine to a participant in a phase 1 trial. Moderna stock climbs 24% over the previous day’s close.
May 18 – Moderna reports early positive data from its phase 1 trial. The company’s stock ends the day up 20% over the previous day’s close.
May 21 – CEO Stéphane Bancel adopts and amends multiple 10b5-1 trading plans.
May 29 – Moderna announces another milestone in its phase 2 coronavirus vaccine trial.
June 1 – President Stephen Hoge amends his 10b5-1 plan.
Despite the close timing, Jordan told NPR, “by the judgment of the legal team, there would not have been material, nonpublic information known” when executives entered into the new plans.
“Every company and individual is entitled to the presumption of innocence. That said, from the public’s perspective, this trading behavior looks very problematic,” said Taylor of the Wharton School, who first pointed out the timing of these changes to NPR.
“If I put on my SEC enforcement hat, I would certainly be asking, ‘What caused you to change the plan on a Friday?'” said Kurt Wolfe, who works as a defense attorney in securities cases for the firm Troutman Pepper. “I don’t think it’s a good fact pattern.”
On May 21 – in between announcements of major vaccine trial milestones on May 18 and May 29 – CEO Bancel amended and adopted 10b5-1 plans. And on June 1, President Hoge amended his trading plan.
“Amending a trading plan after a positive announcement, like trading after a positive announcement, is only problematic if the executive possesses material, nonpublic information at the time,” said Fagel. “Though repeated or questionably-timed changes to a trading plan will reduce its value as a defense to insider trading.”
Selling to zero
Using these 10b5-1 plans, two Moderna executives – Zaks and Andres – have sold all of their shares in the company. General Counsel Lori Henderson has sold nearly all of her shares.
In fact, roughly every week since June, Zaks has exercised stock options (meaning, he bought stock at a price set by the company as part of his compensation), and then immediately sold all of his shares for a significant profit.
[Isn’t this a great explanation for Bancel’s sales too?! – S.m]
On Aug. 24, for example, Zaks exercised stock options and bought 25,000 shares at bargain prices of between $12 to $21. He then immediately sold all of those shares for around $65 per share. Zaks ended up with a profit of nearly $1.2 million.
SEC filings indicate these trades are made under the 10b5-1 plan he adopted in March.
Selling so much stock can also raise concerns for investors – and the public – about why company leaders would sell now if they expected their vaccine to succeed later. After all, a safe and effective vaccine could send Moderna’s stock to even greater heights.
“It perhaps draws questions about how much they believe in it,” said Wolfe.
If the company does develop a safe and effective coronavirus vaccine, and its stock keeps rising, then “these trades will be water under the bridge,” said Fagel, the former SEC enforcement official.
But, Fagel warns, if the vaccine fails, then SEC regulators and angry investors may come looking for answers. In that case, he said, “both class action litigation and an SEC investigation would seem inevitable.”
NPR revelations end here, we’re actually just starting
So what we’ve learned is that Moderna looks like a stock market operation more than a medical one. The chiefs create momentums and then trade. And they use public money to bet and make billions, but more about that shortly.
This news is actually pretext to get you to know the real history of Moderna, a crux point in modern history in the widest sense. The stock dumping is not really news, it’s been happening for quite a while, indicating a long term strategy and business model, rather than a sudden or impulse move.
The next two older reports from Pharma’s own media – STAT, will cement the certainty that Moderna turned into a stock market bubble long ago, under the helms of Stephan Bancel. They don’t mind having some science to show, but that’s just the bait.
Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups
At first glance, Moderna Therapeutics looks like the most enviable biotech startup in the world. It has smashed fundraising records and teamed up with pharmaceutical giants as it pursues a radical plan to revolutionize medicine by transforming human cells into drug factories.
But the reality is more complicated.
A STAT investigation found that the company’s caustic work environment has for years driven away top talent and that behind its obsession with secrecy, there are signs Moderna has run into roadblocks with its most ambitious projects.
At the center of it all is Stéphane Bancel, a first-time biotech CEO with an unwavering belief that Moderna’s science will work — and that employees who don’t “live the mission” have no place in the company. Confident and intense, Bancel told STAT that Moderna’s science is on track and, when it is finally made public, that it will meet the brash goal he himself has set: The new drugs will change the world.
But interviews with more than 20 current and former employees and associates suggest Bancel has hampered progress at Moderna because of his ego, his need to assert control and his impatience with the setbacks that are an inevitable part of science. Moderna is worth more than any other private biotech in the US, and former employees said they felt that Bancel prized the company’s ever-increasing valuation, now approaching $5 billion, over its science.
As he pursued a complex and risky strategy for drug development, Bancel built a culture of recrimination at Moderna, former employees said. Failed experiments have been met with reprimands and even on-the-spot firings. They recalled abusive emails, dressings down at company meetings, exceedingly long hours, and unexplained terminations.
At least a dozen highly placed executives have quit in the past four years, including heads of finance, technology, manufacturing, and science. In just the past 12 months, respected leaders of Moderna’s cancer and rare disease programs both resigned, even though the company’s remarkable fundraising had put ample resources at their disposal. Each had been at the company less than 18 months, and the positions have yet to be filled.
Lower-ranking employees, meanwhile, said they’ve been disappointed and confused by Moderna’s pivot to less ambitious — and less transformative — treatments. Moderna has pushed off projects meant to upend the drug industry to focus first on the less daunting (and most likely, far less lucrative) field of vaccines — though it is years behind competitors in that arena.
The company has published no data supporting its vaunted technology, and it’s so secretive that some job candidates have to sign nondisclosure agreements before they come in to interview. Outside venture capitalists said Moderna has so many investors clamoring to get in that it can afford to turn away any who ask too many questions. Some small players have been given only a peek at Moderna’s data before committing millions to the company, according to people familiar with the matter.
“It’s a case of the emperor’s new clothes,” said a former Moderna scientist. “They’re running an investment firm, and then hopefully it also develops a drug that’s successful.”
Like many employees and former employees, the scientist requested anonymity because of a nondisclosure agreement. Others would not permit their names to be published out of fear that speaking candidly about big players in the industry would hurt their job prospects down the road.
Moderna just moved its first two potential treatments — both vaccines — into human trials. In keeping with the culture of secrecy, though, executives won’t say which diseases the vaccines target, and they have not listed the studies on the public federal registry, ClinicalTrials.gov. Listing is optional for Phase 1 trials, which are meant to determine if a drug is safe, but most companies voluntarily disclose their work.
Investors say it’ll be worth the wait when the company finally lifts the veil.
“We think that when the world does get to see Moderna, they’re going to see something far larger in its scope than anybody’s seen before,” said Peter Kolchinsky, whose RA Capital Management owns a stake in the company.
The Moderna offices in Cambridge, Mass.ARAM BOGHOSIAN FOR STAT
Bancel, meanwhile, said he is aware of the criticism of him and has taken some steps to address it. After scathing anonymous comments about Moderna’s management began showing up online, Bancel went to Silicon Valley to get tips on employee retention from the human resources departments of Facebook, Google, and Netflix. But he makes no apologies for tumult past or present, pointing to the thousands of patients who might be saved by Moderna’s technology.
“You want to be the guy who’s going to fail them? I don’t,” he said in an interview from his glassy third-floor office. “So was it an intense place? It was. And do I feel sorry about it? No.”
An ambitious CEO dreams big
Bancel, 44, had no experience running a drug development operation when one of biotech’s most successful venture capitalists tapped him to lead Moderna. He’d spent most of his career in sales and operations, not science.
But he had made no secret of his ambition.
A native of France, Bancel earned a master’s in chemical engineering from the University of Minnesota and an MBA from Harvard in 2000. As Harvard Business School classmates rushed to cash in on the dot-com boom, Bancel laid out a plan to play “chess, not checkers.”
“I was always thinking, one day, somebody will have to make a decision about me getting a CEO job,” he told an audience at his alma mater in April. “… How do I make sure I’m not the bridesmaid? How do I make sure that I’m not always the person who’s almost selected but doesn’t get the role?”
He went into sales and rose through the operational ranks at pharmaceutical giant Eli Lilly, eventually leading the company’s Belgian operation. And in 2007, at just 34, he achieved his goal, stepping in as CEO of the French diagnostics firm bioMérieux, which employs roughly 6,000 people.
The company improved its margins under Bancel’s tenure, and he developed a reputation as a stern manager who got results, according to an equities analyst who covered bioMérieux at the time.
“He doesn’t suffer fools lightly,” the analyst said, speaking on condition of anonymity to comply with company policy. “I think if you’re underperforming, you’ll probably find yourself looking for another job.”
Bancel’s rise caught the eye of the biotech investment firm Flagship Ventures, based here in Cambridge. Flagship CEO Noubar Afeyan repeatedly tried to entice him to take over one of the firm’s many startups, Bancel said. But he rejected one prospect after another because the startups seemed too narrow in scope.
Moderna was different.
The company’s core idea was seductively simple: cut out the middleman in biotech.
For decades, companies have endeavored to craft better and better protein therapies, leading to new treatments for cancer, autoimmune disorders, and rare diseases. Such therapies are costly to produce and have many limitations, but they’ve given rise to a multibillion-dollar industry. The anti-inflammatory Humira, the world’s top drug at $14 billion in sales a year, is a shining example of protein therapy.
Moderna’s technology promised to subvert the whole field, creating therapeutic proteins inside the body instead of in manufacturing plants. The key: harnessing messenger RNA, or mRNA.
In nature, mRNA molecules function like recipe books, directing cellular machinery to make specific proteins. Moderna believes it can play that system to its advantage by using synthetic mRNA to compel cells to produce whichever proteins it chooses. In effect, the mRNA would turn cells into tiny drug factories.
It’s highly risky. Big pharma companies had tried similar work and abandoned it because it’s exceedingly hard to get RNA into cells without triggering nasty side effects. But if Moderna can get it to work, the process could be used to treat scores of diseases, including cancers and rare diseases that can be death sentences for children.
Bancel was intrigued. He knew it was a gamble, he told STAT, “but if I don’t do it, and it works, I’m just going to kick myself every morning.”
And so he became the company’s CEO — and soon developed an almost messianic reverence for the mRNA technology.
Despite having never worked with RNA before, Bancel said he sat around the table with his core team in the early days of the company, dreaming up experiments. As a result, he is listed as a co-inventor on more than 100 of Moderna’s early patent applications, unusual for a CEO who is not a PhD scientist.
Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine
SAN FRANCISCO — Moderna Therapeutics, the most highly valued private company in biotech, has run into troubling safety problems with its most ambitious therapy, STAT has learned — and is now banking on a mysterious new technology to keep afloat its brash promise of reinventing modern medicine.
Exactly one year ago, Moderna CEO Stéphane Bancel talked up his company’s “unbelievable” future before a standing-room-only crowd at the annual J.P. Morgan Healthcare Conference here. He promised that Moderna’s treatment for a rare and debilitating disease known as Crigler-Najjar syndrome, developed alongside biotech giant Alexion Pharmaceuticals, would enter human trials in 2016.
It was to be the first therapy using audacious new technology that Bancel promised would yield dozens of drugs in the coming decade.
But the Crigler-Najjar treatment has been indefinitely delayed, an Alexion spokeswoman told STAT. It never proved safe enough to test in humans, according to several former Moderna employees and collaborators who worked closely on the project. Unable to press forward with that technology, Moderna has had to focus instead on developing a handful of vaccines, turning to a less lucrative field that might not justify the company’s nearly $5 billion valuation.
“It’s all vaccines right now, and vaccines are a loss-leader,” said one former Moderna manager. “Moderna right now is a multibillion-dollar vaccines company, and I don’t see how that holds up.”
Bancel made no mention of the Crigler-Najjar drug when he spoke Monday before a similarly packed room at this year’s J.P. Morgan conference.
His presentation instead focused on four vaccines that the company is moving through the first phase of clinical trials: two target strains of influenza, a third is for Zika virus, and the fourth remains a secret. Bancel clicked through graphs of data from animal studies before hurrying on to tout Moderna’s balance sheet and discuss the company’s cancer vaccines, slated for clinical testing later this year.
When STAT asked Bancel after the presentation about Crigler-Najjar, he deferred to Alexion.
In need of a Hail Mary
Founded in 2012, Moderna reached unicorn status — a $1 billion valuation — in just two years, faster than Uber, Dropbox, and Lyft, according to CB Insights. The company’s premise: Using custom-built strands of messenger RNA, known as mRNA, it aims to turn the body’s cells into ad hoc drug factories, compelling them to produce the proteins needed to treat a wide variety of diseases.
But mRNA is a tricky technology. Several major pharmaceutical companies have tried and abandoned the idea, struggling to get mRNA into cells without triggering nasty side effects.
Bancel has repeatedly promised that Moderna’s new therapies will change the world, but the company has refused to publish any data on its mRNA vehicles, sparking skepticism from some scientists and a chiding from the editors of Nature.
The indefinite delay on the Crigler-Najjar project signals persistent and troubling safety concerns for any mRNA treatment that needs to be delivered in multiple doses, covering almost everything that isn’t a vaccine, former employees and collaborators said.
The company did disclose a new technology on Monday that it says will more safely deliver mRNA. It’s called V1GL. Last month, Bancel told Forbes about another new technology, N1GL.
But in neither case has the company provided any details. And that lack of specificity has inevitably raised questions.
Three former employees and collaborators close to the process said Moderna was always toiling away on new delivery technologies in hopes of hitting on something safer than what it had. (Even Bancel has acknowledged, in an interview with Forbes, that the delivery method used in Moderna’s first vaccines “was not very good.”)
Are N1GL and V1GL better? The company has produced no data to answer that question. When STAT asked about new technologies, Bancel referred questions to the company’s patent filings.
The three former employees and collaborators said they believe N1GL and V1GL are either very recent discoveries, just in the earliest stages of testing — or else new names slapped on technologies Moderna has owned for years.
“[The technology] would have to be a miraculous, Hail Mary sort of save for them to get to where they need to be on their timelines,” one former employee said. “Either [Bancel] is extremely confident that it’s going to work, or he’s getting kind of jittery that with a lack of progress he needs to put something out there.”
Former employees and collaborators who spoke with STAT requested anonymity because they had signed nondisclosure agreements — which the highly secretive Moderna requires even some job candidates to sign.
A STAT investigation last year found that Bancel had driven away top talent from Moderna with a culture of recrimination and a caustic work environment, including on-the-spot firings for failed experiments.
The company, based in Cambridge, Mass., seems to have repaired its reputation among many rank-and-file employees, winning workplace accolades from Science Magazine and the Boston Globe, but Moderna has lost more than a dozen top scientists and managers in the past four years, despite its vast financial resources.
A bug in the software
Bancel, a first-time biotech CEO, has dismissed questions about Moderna’s potential. He describes mRNA as a simple way to develop treatments for scores of ailments. As he told STAT over the summer, “mRNA is like software: You can just turn the crank and get a lot of products going into development.”
It seems clear, however, that the software has run into bugs.
Patients with Crigler-Najjar are missing a key liver enzyme needed to break down bilirubin, a yellowish substance that crops up in the body as old red blood cells break down. Without that enzyme, bilirubin proliferates in the blood, leading to jaundice, muscle degeneration, and even brain damage.
In Moderna’s eyes, the one-in-million disease looked like an ideal candidate for mRNA therapy. The company crafted a string of mRNA that would encode for the missing enzyme, believing it had hit upon an excellent starting point to prove technology could be used to treat rare diseases.
But things gradually came apart last year.
Every drug has what’s called a therapeutic window, the scientific sweet spot where a treatment is powerful enough to have an effect on a disease but not so strong as to put patients at too much risk. For mRNA, that has proved elusive.
Before COVID-19, the company’s secretive nature, and its failure to deliver a functional product, was drawing comparisons to the infamous biotech startup Theranos. Similar to Moderna, Theranos rarely published any peer-reviewed material. Like Moderna, Theranos mastered the networking game, and recruited high profile individuals to its board in order to vouch for the company’s “revolutionary technologies.” Once valued at well over $10 Billion, Theranos collapsed after it was revealed that the company was running a massive fraud scheme, in addition to its failure to implement its promised blood testing technology.
“Now an obscure lawsuit filed in British Columbia in October sheds light on one of Moderna’s key partners, and through it FORBES can reveal details on Moderna’s amazing but still untested technology.
It appears that the first two products Moderna has entered into clinical trials rely on technology from a small outfit in Vancouver, British Columbia, called Acuitas Therapeutics. (Acuitas is so small, in fact, that its worldwide headquarters are in its CEO’s single-family home.)
Almost all medicines either block proteins–the building blocks of life–or, in the case of expensive biotech drugs, are proteins themselves. But Moderna has been promising to hack an entirely different part of life’s cookbook. In order to turn genetic information encoded in DNA into the cellular machines that actually are proteins, living things use a messenger chemical called mRNA.
Creating these mRNA drugs is a big challenge on many levels. For them to work, Moderna needs to deliver mRNA to the body’s cells. By itself mRNA breaks down in the bloodstream. Tiny Acuitas specializes in one method: lipid-nanoparticle delivery systems. Its technology essentially wraps the mRNA into balls of fat that disguise the drug so that the target cells will readily ingest it.
“Although we are small,” says Thomas Madden, chief executive of Acuitas, “I believe the technology we have developed is highly effective.”
The problem for Madden and Moderna is that Acuitas doesn’t actually own the technology it has licensed to Moderna. The tech belongs to a third company, publicly traded Arbutus, which recently decided to terminate the license for the tech that it had granted to Acuitas. That’s why Acuitas filed the lawsuit in British Columbia, to protect the deal it had. Arbutus immediately countersued, claiming its deal with Acuitas didn’t cover Moderna’s medicines.
The legal mess has its roots in Moderna’s 2011 start, when Robert Langer, an MIT professor, Moderna board member and founder of dozens of biotech companies, told Bancel that Moderna was too underfunded and small to create its own delivery system. So Moderna vetted over a dozen external delivery methods for mRNA and settled on at least three. One belonged to Arbutus, but Moderna turned to tiny Acuitas to get access to it.
Acuitas was formed in 2009 by Madden after a merger eliminated his position at Arbutus’ predecessor, Tekmira Pharmaceuticals. After a contentious lawsuit Madden was able to license from his former employer the novel tech he had helped develop, and Bancel claims Moderna chose to work with Acuitas because it had “the people and the capabilities.”
But that doesn’t explain why Moderna–flush with capital–didn’t make sure that sublicensing through Acuitas would be okay with Arbutus before advancing its new drugs into human studies.
Bancel met with FORBES at a Brooklyn coffee shop on a recent Saturday to dispel the implications of the lawsuit. He is dismissive of Acuitas’ technology. “We knew it was not very good,” he says. “It was just okay.”
He further explains that Moderna is in the process of producing its own nanoparticle lipids. One such lipid, N1GEL (called “Nigel” internally), appears to cause less inflammation than Acuitas’ version. Another is being licensed from Merck. Bancel says Moderna has stopped using the Acuitas tech for new drugs.
That still leaves a somewhat messy situation for any Moderna vaccines that are being developed using Acuitas’ tech.
Data from one vaccine is expected early next year. If results are good, it could lead to a sizzling-hot initial public offering, even if the Canadian lawsuit ultimately affords Arbutus bigger royalty payments from Moderna.”
Well, the two tiny Canadian companies mentioned above bring royalties to the Canada’s treasury (should I say The British Crown?), so don’t expect Trudeau to backpedal too soon
AND IF ONLY THEY HUSSLED WITH PRIVATE FUNDS, AS THEY CLAIMED…
Moderna chief keep claiming that they started to use public funds only as a patch on infrastructure, science and funding they’ve built for years.
Wrong!
It’s known that NIH + NIAID have long been one of their main sources for the “lavish funding” mentioned earlier and when they locked in the government support, they actually started to leverage it and attract even more private funds, in an self-feeding loop that created today’s monster-bubble.
Very few people know they even got money from BARDA and DARPA. As in “military funds”.
Remember this lie from earlier? “The company has been funded over the years by billions of dollars of private investment,” Zaks told the Freakonomics podcast in August. “Those billions created the opportunity for the U.S. government to come in earlier this year and say, ‘I’m going to add some money to the pot to make sure that you get the development for this vaccine right.'” Watch this claim getting nuked:
This grid above looks familiar to you? It does to me, but it’s not blood from people who underwent Covid genetic therapies, just something similar. Taken from:
KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents
by Knowledge Ecology International (KEI)
Luis Gil Abinader has taken a deep dive into Moderna’s surprising practice of never declaring government funding in its 126 patents and 154 patent applications, despite having had funding from multiple federal agencies.
One outcome of his research is a 25 page report (RN-2020-3) on Moderna’s failure to report funding from DARPA, and a request by KEI to DOD and DARPA to remedy this, including by taking title to patents where disclosures should have been made. (Text of letter below, and PDF version here).
KEI will also send a letter to BARDA. The letter below was addressed to DOD and DARPA, and focuses on their funding.
Context
The obligation to disclose federal funding in patent applications has been subject to presidential executive orders, statutes, regulations and contracts, including those cited and quoted in Abinader’s report. The disclosure clarifies the public’s rights in the inventions and the obligations on the entity getting the money, on everything from the government’s worldwide royalty free license to the public’s march-in rights, obligations to make inventions available to the public on reasonable terms, and additional safeguards that can be exercised by a government inclined to do so.
Secondly, the disclosure changes the narrative about who has financed the inventive activity, often the most risky part of development.
One of the earlier norms on this was Franklin Roosevelt’s Executive Order 9424, on the Establishment of a Register of Government interests in patents.
In 2018, the regulations on disclosure were modified by NIST (see 83 FR 15954), where, among other things, the government gave itself unlimited time to remedy a failure to disclose federal funding, to eliminate one loophole that created an incentive ignore the disclosure requirement.
In the past, the US Department of Defense has taken title to patents where federal funding was not disclosed. See: Campbell Plastics v. Brownlee, 389 F.3d 1243 (Fed. Cir. 2004).
The research on the Moderna/DARPA funding is outlined in a 25 page August 27, 2020 report by Luis Gil Abinader, titled: “Moderna failures to disclose DARPA funding in patented inventions.” RN-2020-3
Below is the text of the KEI letter to Dr. Mark T. Esper, Secretary of Defense, and Dr. Amy Jenkins, of the Pandemic Prevention Platform for the Defense Advanced Research Projects Agency (DARPA), regarding the apparent failure by Moderna to disclose DARPA funding in patent applications. PDF copy here:
2020. September 18. DARPA letter to KEI confirming investigation of Moderna for failure to report government funding in patent applications. https://www.keionline.org/33970
2020. September 4. BARDA is investigating Moderna’s failures to disclose BARDA funding in patent applications. https://www.keionline.org/33907
2020. September 2. KEI request to BARDA concerning Moderna obligations to disclose federal funding in patent applications. https://www.keionline.org/33892
2020. August 30. DARPA announces investigation into Moderna’s apparent failures to disclose mRNA vaccine patents. https://www.keionline.org/33832
2020. August 28. KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents. https://www.keionline.org/33763
2020. August 27. 2020:3 KEI Research Note: Moderna failures to disclose DARPA funding in patented inventions. https://www.keionline.org/rn-2020-3
2020. August 5. BARDA Responds to KEI, Public Citizen Letter Asking BARDA to Enforce Moderna Contract. https://www.keionline.org/33633
2020. August 4. KEI and Public Citizen request BARDA to address Moderna’s noncompliance with COVID-19 vaccine contract term. https://www.keionline.org/33618
2020. July 1. KEI receives seven new contracts for COVID 19 research from BARDA and DOD, including five using “Other Transactions Authority” that weaken or eliminate Bayh-Dole and FAR Safeguards. https://www.keionline.org/covid19-ota-contracts
Washington Post 2020. August 28. “Moderna failed to disclose federal support in vaccine patents, researchers say: The company with a leading coronavirus vaccine candidate did not adhere to a law designed to protect public investment.” Washington Post. Christopher Rowland. https://www.washingtonpost.com/business/2020/08/28/moderna-vaccine-patents-darpa-funding/
Financial Times 2020. August 29. “US government’s Darpa probes Moderna’s vaccine patents: Researchers accuse biotech company of failing to disclose federal grants in patents which also cover Covid-19 candidate.” Financial Times. Donato Paolo Mancini. https://www.ft.com/content/2be1f87e-9e96-4e23-9cc5-33ba35e50586
Moderna’s vaccine was developed with support from the NIAID, and, as covered in a past fact check, analysis from Axios found that the National Institutes of Health, of which the NIAID is part, may own intellectual property used in producing Moderna’s vaccine. Dr. Francis Collins, director of NIH, has also said that NIH has a stake in intellectual property used in the vaccine, though what exactly this means in practical terms is unclear.
“Valera’s efforts (Moderna subsidiary) have resulted in the demonstration of preclinical efficacy of Moderna’s mRNA-based vaccines in multiple viral disease models, Moderna said.
In the partnership with the Gates Foundation, Valera will apply its mRNA vaccine platform as well as Moderna’s drug platform Messenger RNA Therapeutics™. Designed to produces human proteins, antibodies, and entirely novel protein constructs inside patient cells, the therapeutics are secreted or active intracellularly.” – Genetic Engineering & Biotechnology News
To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus. He stepped down but he didn’t give up his stakes in Moderna, as the Daily Beast reports:
“Slaoui’s ownership of 156,000 Moderna stock options, disclosed in required federal financial filings, sparked concerns about a conflict of interest. Democratic Massachusetts Senator Elizabeth Warren called Slaoui out over the matter on Twitter: “It is a huge conflict of interest for the White House’s new vaccine czar to own $10 million of stock in a company receiving government funding to develop a COVID-19 vaccine. Dr. Slaoui should divest immediately.” The company’s shares skyrocketed last month after news broke of the $483 million in federal funding to work on a coronavirus vaccine. Slaoui could not immediately be reached for comment on the matter.”
Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation
So this has never been about health, just a global scale racketeering operation that’s coming to light about about to go bust. You can speed up this process simply by spreading this expose far and wide!
UPDATE MARCH 21, 2022: VOILA!
Via our ex-BlackRock friend Edward Dowd. I rest my case, but I bet they will “unrest” it soon.
Both Pfizer+Moderna have issued huge 2022 revenue guidance to Wall Street for C-19 vaccines: combined nearly 3 billion doses & ~$50b in revenue.
But mRNA demand has waned.
If they don't sell 4th doses, they may need to break their promises to Wall St. and lower their guidance. pic.twitter.com/K0HMdfFBPu
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Ivanka Trump being a Young Global Leader at Davos 2020
Dr. Oz aka Dr. Why
WAIT, IT GETS EVEN DEEPER, BELIEVE IT OR NOT!
Trumpies stuck forks in their own eyes to avoid seeing this and I don’t speak to leftoids, so it went largely overlooked in 2020, but I think it aged smoothly. Don’t perpetuate that grave error, see:
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Only days ago, Luc Montagnier was up in arms on the barricades against Covidiocracy. Suddenly, he is told to have left the battlefield, in peace, not as a fallen general. Why such a sudden ‘change of heart’? This is the question.
Got around doing a little video summary, but the devil is in the details below.
“At the age of 89 (August 18, 1932 – February 8, 2022), Professor Luc Montagnier died at the American Hospital in Neuilly-sur-Seine. Doctor Gérard Guillaume, one of his most faithful collaborators, tells us that he left in peace, surrounded by his children.
He was a biologist and virologist, but also and above all a man of remarkable intelligence, who lived for science. In addition to having been named Nobel Prize for Medicine in 2008 for the discovery of the AIDS virus, he worked alongside the greatest scientific institutes in the world during his life. Emeritus research director at the CNRS, professor at the Institut Pasteur, director of the Center for Molecular and Cellular Biology at Queens College of the City University of New York, director of a research institute at the Jiao-tong University of Shanghai. He supported the Academy of Sciences as well as the National Academy of Medicine through his research for many years. For this, he has received countless awards and accolades.
Despite his advanced age and despite all the criticism he suffered in the autumn of his life, notably from part of the scientific community, Luc Montagnier has always fought for free science. We were lucky enough to be able to welcome him several times at FranceSoir, and would like to give him all the honors that are due to him.” – France Soir
Many call this death ‘sudden’, as in “unforeseen”.
Others. such as myself, have been wondering for long why is he still allowed to roam free and blow the whistle, given his deep involvement with the AIDS scam, his out-spoken anti-Pharmafia stance and, more recently, his total dissidence to the Covid / vaccine narrative.
Rare video from World Health Summit, 2010
“His death took place on Tuesday 8 February, on the same day as the funeral of the Italian biologist Franco Trinca struck down by a very violent and suspicious form of Covid-19 despite being in excellent health and used to take care of himself with a thousand precautions. Trinca had often taken up the complaints of the internationally renowned French scientist who, having worked in the field of vaccines, had denounced the dangers of gene serums based on messenger RNA above all for the risk of creating degenerative brain diseases from prions, as highlighted in our latest investigation.” – VT
Information surrounding his death are inexistent yet, I’m writing this less than 12h after the official announcement. I will add here anything relevant to it, as much as to why he was a major threat to Pharmafia and the WEF cartel.
UPDATE: Associated Press and thus the global mainstream media finally caught up but still no additional info, just more character assassination rituals.
LAST TIMES HE APPEARED IN PUBLIC:
Four weeks before Montagnier’s death:
“On January 9, Montagnier once again appeared on an international media, the Wall Street Journal, in an editorial titled Omicron makes Biden’s vaccination obligations obsolete, co-signed by American constitutionalist Jed Rubenfeld who another disgraced celebrity: married to Amy Chua, fellow law professor at Yale and author of the world bestseller on the mother tiger, Rubenfeld accused of sexual assaults on female students and suspended by Yale for two years. After the article on the Wsj and before the intervention in Milan, Luc Montagnier appeared last Wednesday in the Luxembourg House of Parliament to support a petition against compulsory vaccination, but his commitment against vaccines began well before the Covid era.” – Italy24 News
“Luc Montagnier, who in 2009 suggested fighting AIDS with better nutrition, he is experiencing an unexpected return these days, accompanied as always by the American assistant and companion Suzanne McDonnell Long, who was next to him in Milan when he added that it was a crime to give this vaccine to children. As in the past, when Montagnier sold expensive papaya preparations in pharmacies, the problem that the professor does not provide any proof of what he claims. His sentences are not based on any research he has done in recent months or years, but respect for the scientific community is not something that would interest him or his followers.” – Italy24 News
So he almost literally died on the barricades…
Last time I checked…
New evidence, including sworn affidavits from leading experts such as Professor Luc A. Montagnier, has been submitted to the International Criminal Court by lawyers in several countries alleging Government’s across the world and their advisors are complicit in genocide, crimes against humanity and breaches of the Nuremberg Code. – Daily Expose
“Attorney Melinda C. Mayne, and Kaira S. McCallum submitted a 27-page ‘Request for Investigation’ to the International Criminal Court (ICC) at The Hague back in April 2021 alleging the UK Government and its advisors were complicit in crimes against humanity in the name of Covid-19.
On the 28th of April 2021, the pair received a formal acknowledgement from the ICC and were assigned a case number – ‘141/21’. Since then the pair have been gathering new evidence to use in their ICC claim and have established connections with lawyers and research scientists from around the world.
A new press release released on the 17th August, which can be viewed here, confirms that the pair have received sworn affidavits from leading experts including research scientist and nuclear cardiologist Dr Richard M. Fleming, the Nobel Laureate virologist Professor Luc A. Montagnier, and Dr Kevin W. McCairn, a neuroscientist and expert on neurological disease.
Professor Luc A Montagnier, who won a Nobel prize for his work on the HIV virus, claimed in April 2020 that he believed the novel coronavirus was created in a laboratory. Then in May 2021 the expert virologist stated that “Mass vaccinations are a scientific error as well as a medical error. It is an unacceptable mistake. The history books will show that, because it is the vaccination that is creating the variants”.
A new claim has also been submitted to the ICC due to the vast amount of new evidence and information that has come to light in the past few months, and the lawyers say they now have compelling evidence that “the SARS-CoV-2 virus and the Covid-19 ‘vaccines’ are deliberately engineered bioweapons that have been released in two phashes on unsuspecting peoples of the world”.
Attorney Melinda C. Mayne, and Kaira S. McCallum have also confirmed that they have now be joined by lawyers who have filed similar Requests for Investigation to the International Criminal Court, in France, the Czech Republic and Slovakia.
Because of this a letter was sent to the ICC on the 12th August 2021 requesting they all be allowed to submit a joint claim, whilst also submitting preliminary evidence for the allegations common to everyone across the world, and requesting the right to have claims specific to individual countries also investigated by the ICC.” – Daily Expose
They called him a “conspirationist” because he was an early adept of the Chinese lab origin of the virus
KARy MULLIS, THE PCR INVENTOR, DIED JUST A FEW MONTHS BEFORE COVID. DID MONTAIGNER, THE HIV DISCOVERER, DIE JUST MONTHS BEFORE A BIG AIDS RESURGENCE?
— Chris Wymant @chriswymant.bsky.social (@ChrisWymant) February 4, 2022
Instead of AIDS, I’d call that, and I’m not the only one, “Vaccine-Induced Auto-Immune Syndrome”, but let’s pretend we go along with the official narrative.
Logically, Montaigner should’ve been the first to summon with the Bat Signal.
That never happened. His death happened.
The day Montagnier died:
This was aired in US on the day Montagnier died.
I think we need a recap. we’ll start here and I will gradually build a picture, come back later:
WUHAN-GATES – 3. “COVID-19 Created in Lab with HIV”. Medicine Nobel confirms Indian Research disclosed byGospa News
Luc Montagnier, the French virologist Nobel Prize winner for Medicine in 2008 for his AIDS research
In 7 lines, one of the world’s leading experts in medicine makes “tabula rasa” of somewhat sibylline hypotheses so far promoted by virologists, perhaps even induced by some housekeeper worried about national security in the face of the confirmation of a pandemic capable of causing 120 thousand deaths.
His words carry enormous weight: because in 2008 Montagnier discovered the human immunodeficiency virus HIV as the cause of the AIDS epidemic so much that he won the Nobel Prize for Medicine together with Françoise Barré-Sinoussi and Harald zur Hausen.
«Coronavirus would be a manipulated virus, accidentally released from a Chinese laboratory in Wuhan where the AIDS vaccine was being studied. Professor Luc Montagnier said so» writes the Italian Journalism Agency (AGI), one of the few big media to report the news with prominence.
However, it publishes it with less evidence compared to another article on the statements of the American immunologist Anthony Fauci, director of the American National Institute of Allergy and Infectious Diseases, who persistenly supported the natural origin of the virus.
It is therefore understandable that the American doctor tries to divert attention from the hypothesis of a pathogen manipulated by bioengineering since the most disturbing experiment was conducted by the biosafety 3 of the Burnett Womack Biohazard center at the Chapell Hill site of the University of North Carolina together with the biosafety laboratory 4 of the Wuhan Institute of Virology.
Not only. The research had been supported by the institute where Fauci works through «grants from the National Institute of Allergy & Infectious Disease and the National Institute of Aging of the United States National Institutes of Health (NIH), the National Natural Science Foundation of China and the USAID-EPT-PREDICT funding from EcoHealth Alliance» as stated in the Abstract published by Nature Medicine published in report no. 9.
The trial led to «building a chimeric CoV with a bat CoV S gene (SHC014) in the backbone of a SARS CoV that has adapted to infect mice (MA15) and is capable of infecting human cells».
But in the supervirus study conducted primarily in the Chapel Hill laboratories of the University of North Carolina, mention that was also made experiments «similar to those using an HIV-based pseudovirus, prepared as previously described and tested on HeLa cells (Wuhan Institute of Virology) which the ACE2 orthologists expressed».
Therefore he is by no means extraneous to matters connected with China and certainly knows Wuhan’s laboratory strongly desired by the entourage of former president Jiang Zemin, historic leader of the Chinese Communist Party who has become popular in the world for international trials for human rights violations in Tibet and for the nickname “executioner of Tiananmen”.
Porquoi Docteur’s scoop with the interview with Montagnier
«The hypothesis is that this virus leaves the Wuhan laboratory. It is a high security laboratory but despite all the virus has escaped from the control of the promoters. The history of the fish market is a beautiful legend but it is not possible that it is only a virus transmitted by a bat, it is probably from this that they started, then they modified it. Maybe they wanted to make an AIDS vaccine using a coronavirus as an antigen carrier. A work of sorcerer’s apprentices can be said. Because we must not forget that we are in the world of nature, there are balances to be respected» said Montagnier peremptorily.
According to the scientist, the altered elements of this virus will however be eliminated as it spreads: «Nature does not accept any molecular manipulation, it will eliminate these unnatural changes and even if nothing is done, things will improve, but unfortunately after many deaths».
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
SILVIEW.media 